Cornerstone Wealth Senior Investment Analyst Sean Bandazian and Opimas CEO Octavio Marenzi examine the conditions surrounding fresh market gains following Fed Chair Powell's latest rate hike comments, while also discussing the market outlook, inflation, and mortgages in the housing market.
Rather than counting on what could happen in China, let's check the charts and indicators for this electric vehicle name.
Shares of Salesforce fell despite the company's Q3 earnings beat after news of co-CEO Bret Taylor resigning and weakened fourth-quarter guidance.
Rushing to buy Chinese electric car stocks after an earnings miss, are investors making a big mistake?
The richest man in the world runs five companies. And he never hesitates to let the world know what he thinks.
Yahoo Finance Live checks out Xpeng shares following the EV developer's latest earnings report and production figures.
Yahoo Finance Live's Seana Smith checks out several stocks trending in the after-hours trading session.
Sorrento Therapeutics Inc (NASDAQ: SRNE) released topline Phase 2 SAD/MAD study data of its oral main protease (Mpro) inhibitor, STI-1558, conducted in 58 healthy volunteers in Australia. The SAD portion of the study evaluated doses from 300 mg to 2,000 mg, and the MAD portion evaluated 300 mg, 600 mg, or 800 mg BID (twice daily) for 7.5 days. In addition to the Mpro inhibition, which can block viral replication, STI-1558 has cathepsin L inhibition, preventing viral entry into the host cell. Rel
Florida Gov. Ron DeSantis didn't wait long after his reelection to take another shot at The Walt Disney Co. — a powerhouse company the state has boxed this year. DeSantis, via his Twitter account, posted a clip from an appearance on Fox News' Tucker Carlson Tonight where he commented on a recent Disney town hall at which new-yet-returning CEO Bob Iger discussed the state's ongoing feud with Disney.
Shares of Horizon Therapeutics (NASDAQ: HZNP) were skyrocketing 27.2% higher as of 10:48 a.m. ET on Wednesday. The big jump came after the company announced Thursday evening that it's in discussions with Amgen (NASDAQ: AMGN), Johnson & Johnson (NYSE: JNJ) subsidiary Janssen, and Sanofi (NASDAQ: SNY) about potentially being acquired. There were two words in Horizon's press release that investors should note: "highly preliminary."
While the data has checked many of the boxes that suggest the U.S. is in the midst of a recession, other metrics contradict that conclusion, leaving investors uncertain about where we stand. A key economic indicator released on Wednesday provided a bit of clarity, suggesting things are actually better than some had feared. With that as a backdrop, semiconductor specialist Taiwan Semiconductor Manufacturing (NYSE: TSM) climbed 1.8%, streaming video pioneer Roku (NASDAQ: ROKU) jumped 2.7%, and e-commerce platform Shopify (NYSE: SHOP) rallied 3.3% as of 1:11 p.m. ET on Wednesday.
I will be 72 years old on Feb. 10, 2023. I have a traditional individual retirement (IRA) account. Most of the money is tied in stocks, and the stocks this year are way down. If I sell to pay the … Continue reading → The post Ask an Advisor: When Taking RMDs, How Do I Avoid Locking in Losses? I'll Be 72 Years Old Soon, and My Stocks Are ‘Way Down' This Year appeared first on SmartAsset Blog.
Several fintech stocks reversed course and moved higher this afternoon after Federal Reserve Chair Jerome Powell, during a highly anticipated press conference, said that the Fed is preparing to slow the pace of its interest rate hikes. Shares of the artificial intelligence-assisted lending platform Upstart Holdings (NASDAQ: UPST) traded nearly 3% higher in the final hour of trading today. Meanwhile, shares of the digital bank SoFi Technologies (NASDAQ: SOFI) traded nearly 4% higher, and shares of the buy now, pay later company Affirm Holdings (NASDAQ: AFRM) were up close to 6%.
Shares of Meta Platforms (NASDAQ: META), Etsy (NASDAQ: ETSY), and Airbnb (NASDAQ: ABNB) were catching an afternoon breeze after Federal Reserve Chair Jerome Powell made dovish remarks in a speech today. As of 2:45 p.m. ET, the Nasdaq was up 2.9%, while Meta had gained 6.4%, Etsy was up 4.7%, and Airbnb was up 4.3%. Speaking at the Brookings Institution, Powell said that the central bank could slow the pace of rate increases at the next FOMC meeting on Dec. 13-14.
Rivian's CEO has investors seemingly content with its current status, and looking forward to its upcoming R2 vehicle platform.
Pharmaceutical giant Pfizer (NYSE: PFE) is no stranger to investors; the company is a longtime staple in the healthcare industry. It got a lift in late 2020 and in 2021 as one of the COVID-19 vaccine suppliers, but investors seem to have grown bored with Pfizer's story, and the stock is down about 16% since the start of 2022. The thing is, investors shouldn't be so quick to write off Pfizer stock.
The S&P 500 jumped above the key 200-day level on Fed chief Powell's comments. But inflation data and the jobs report loom.
Americans trying to save some cash for unforeseen expenses are up against a lot — months of red-hot inflation, wages that don’t keep up, the sheer difficulty of delayed gratification in a time when people spend billions of dollars online in one day. “It won’t happen, it has never happened and unless employers start to help employees do that, we’re heading, really, down hill very fast,” she said. The savings rate has not been helped by the end of pandemic-era government benefits.
Standing here at the tail end of 2022, we can see the next year through the mist of uncertainty – and for now, that view is dominated by high inflation, rising interest rates and potential recession. Looking at the market situation, Goldman Sachs strategist Christian Mueller-Glissmann writes: "We remain defensive for the 3-month horizon with further headwinds from rising real yields and lingering growth uncertainty... The growth/inflation mix remains unfavorable – inflation is likely to normaliz
Aeglea BioTherapeutics Inc (NASDAQ: AGLE) has appointed Jeffrey M. Goldberg as president, chief executive officer, and a board member, effective November 29, 2022. Jim Kastenmayer will step down as interim chief executive officer and retain his position as Aeglea's general counsel. Following the leadership transition and as part of the related evaluation of near-term corporate and clinical development strategy, Aeglea no longer plans to announce interim clinical data from the ongoing Phase 1/2 t